Is Tirzepatide Available on the NHS — and What Does the Evidence Say?

What NICE actually decided, and the phased rollout it triggered

In December 2024 NICE published Technology Appraisal TA1026, recommending tirzepatide (Mounjaro) for weight management in adults on the NHS. The decision followed the SURMOUNT clinical programme, whose headline trial showed an average body-weight reduction of around 20–21% over 72 weeks at the highest dose, figures that, at the time, represented the strongest results of any licensed treatment in this class. NICE's approval was significant, but the recommendation came with a deliberate phased structure. The committee and NHS England agreed that opening access to every eligible adult simultaneously would not be practical, so eligibility is being released in steps tied to BMI thresholds and the number of qualifying conditions a person carries.

The qualifying conditions are: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. Only these five count toward the threshold. That list matters because it determines which cohort a patient falls into, and therefore when their GP can formally prescribe. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, BMI thresholds are set 2.5 kg/m² lower throughout the rollout. NHS England's weight-management injections guidance covers these thresholds in detail.

Meeting the criteria does not guarantee access. Every NHS patient is also required to take part in wrap-around diet and activity support alongside treatment, and GP practices can only prescribe if they have opted into the relevant contract arrangements, participation is voluntary, so coverage differs across England. Scotland, Wales and Northern Ireland apply different criteria and timelines.

The phased schedule: which cohorts are open and when the rest follow

The rollout is tied to specific activation dates. The first cohort (adults with a BMI of 40 or above and four or more of the five qualifying conditions) opened from June 2025. From 23 June 2026 a second cohort became eligible: adults with a BMI between 35 and 39.9 who also carry four or more conditions. A third cohort, covering BMI 40 or above with three or more conditions, is expected around March 2027, with further expansions scheduled after that.

In practical terms, this means the majority of adults who could benefit from tirzepatide are still outside the NHS eligibility window today. Someone with a BMI of 38, type 2 diabetes, and high blood pressure has two qualifying conditions, not the four currently required. They would not yet be eligible under NHS criteria, regardless of how much the medicine might help them clinically.

If you're trying to understand where you stand within the NHS timeline, our page on when Mounjaro will be available on the NHS maps out each phase in detail. For a broader look at the Mounjaro licence itself, the Mounjaro overview covers how the medicine works and who it's licensed for privately.

Private prescribing: who it's for and how it works in practice

If you don't meet the current NHS criteria (or you do meet them but face a long wait at your GP practice) a private prescription is the other legal route. Tirzepatide is a prescription-only medicine under UK law, which means the process always begins with clinical assessment rather than a direct purchase. A GPhC-registered prescriber reviews your health information personally before any prescription is issued. That applies whether you're seen in a clinic or through a regulated online pharmacy.

At this point it's worth being honest about something: many people reading this feel a quiet frustration. The NHS criteria feel arbitrary when you're living with a weight-related condition that isn't on the list of five, or when your BMI sits just below the current threshold. That frustration is understandable. The phased structure exists for commissioning reasons, not because your situation is any less real.

A private prescription through a service like ours has no waiting list and no referral requirement. Eligibility mirrors the licensed indication: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. You'll find the treatment pricing set out transparently, one price that includes the consultation, the prescription, and tracked delivery, with no subscription and no auto-renewal. If you're stocking up or want to reduce the cost per dose, you can find out more about how our multi-buy Mounjaro options work. Every repeat order goes through a fresh clinical review before dispatch. For anyone considering the private route, our guide to getting a Mounjaro prescription privately explains what that process involves.

What to consider before deciding which route suits you

Choosing between the NHS and private prescribing isn't just about speed. On the NHS, treatment is free at the point of use if you qualify, but it comes with geography-dependent availability, mandatory wrap-around programme participation, and the phased criteria above. Privately, you pay for the medicine and service but gain speed, flexibility and a straightforward clinical pathway, provided you use a pharmacy you can verify as legitimate.

Checking a pharmacy's registration takes under a minute. The GPhC pharmacy register lists every legally operating online pharmacy in the UK; any pharmacy dispensing prescription medicines should appear there. Red flags include sellers offering these medicines without a prescription, prices far below the market range, or discount codes tied to a specific medicine, none of which are consistent with legitimate, clinically supervised supply. The MHRA has issued repeated warnings about counterfeit GLP-1 pens, and the consequences of using unverified sources have been serious for some patients.

If you're weighing different treatment options more broadly, or want to understand how the NHS rollout compares for those already on treatment, our page on Mounjaro's NHS weight-loss indication goes into the clinical context. And for a summary of Mounjaro's overall NHS availability, including what the current commissioning landscape looks like for GPs, there's more detail there too.